Clinical Trials at START Midwest
As of June 2026, 61 paid clinical trials are recruiting at START Midwest, located at 750 FRONT AVE NW STE 311, GRAND RAPIDS, MI 49504-4400, phone (616) 459-8971 in Grand Rapids, Michigan. Active studies at this site cover conditions such as Colorectal Cancer, Advanced Solid Tumor and Advanced Solid Tumors. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
61 clinical trials at START Midwest
·Clear filters·↓ Download CSVStudy to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
A Study of ZW251 in Participants With Advanced Solid Tumors
TLN-372 in Advanced KRAS Mutant Solid Tumors
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
ARC101 in Advanced Solid Tumors
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
About research studies in Grand Rapids
Grand Rapids has approximately 443 recruiting research studies across a wide range of therapeutic areas. Michigan hosts University of Michigan Health, Henry Ford Health, and Corewell Health, running trials across oncology, neurology, and cardiology with a strong focus on precision medicine.
Common conditions studied in Grand Rapids
- Colorectal Cancer (15 active studies). Colorectal cancer trials explore novel chemotherapy combinations, targeted agents, and immunotherapy for microsatellite-instability-high tumors.
- Advanced Solid Tumor (14 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Advanced Solid Tumors (14 active studies). Recruiting Advanced Solid Tumors studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Breast Cancer (12 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Ovarian Cancer (10 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Colorectal Neoplasms (9 active studies). Recruiting Colorectal Neoplasms studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Grand Rapids
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
- AstraZeneca
- Children's Oncology Group
- Merck Sharp & Dohme LLC
Local regulations and guidelines
Clinical trials in Michigan are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Michigan research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Grand Rapids. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Grand Rapids
Hipa.ai aggregates every recruiting study in Grand Rapids from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Grand Rapids?
There are approximately 443 recruiting clinical trials in Grand Rapids, Michigan listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Grand Rapids pay participants?
Most recruiting trials in Grand Rapids compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Grand Rapids?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Grand Rapids?
The most common conditions under active study in Grand Rapids include Colorectal Cancer (15), Advanced Solid Tumor (14), Advanced Solid Tumors (14), Breast Cancer (12), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Grand Rapids?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Grand Rapids on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Grand Rapids?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Grand Rapids?
Recruiting research sites in Grand Rapids include Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Trinity Health Grand Rapids Hospital, Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Grand Rapids right now?
The largest active categories in Grand Rapids are Cancer & tumors (238), Cardiovascular (25), Neurology & pain (14). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of START Midwest?
START Midwest is located at 750 FRONT AVE NW STE 311, GRAND RAPIDS, MI 49504-4400. Use the Google Maps link in the intro above to get directions.
How do I contact START Midwest?
You can reach START Midwest by phone at (616) 459-8971. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.